When abdominal tuberculosis occurs in the context of multidrug-resistant tuberculosis (MDR-TB), a dedicated, specifically structured treatment regimen is required. This page outlines the clinical scenario and points to the full evidence-based protocol.
Multidrug resistance is documented across a significant share of TB patients: MDR strains have been identified in 2.4–13.2% of isolates from newly diagnosed cases, and in 17.4–25.5% of previously treated patients. Abdominal tuberculosis arising in this context falls under the MDR-TB treatment pathway.
Management follows the WHO shorter MDR-TB regimen — a structured multi-phase combination approach that incorporates an injectable agent together with several oral antimycobacterials. The full composition of each phase, phase durations, sequencing, and dosing guidance are specified in the complete protocol.
The key monitoring milestone is sputum smear status at the end of month 4. A negative smear at that point confirms the standard treatment course; a positive smear at that stage triggers an extension of the initial treatment phase before the regimen continues.